News

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...